ReviewLeukemia2020
Systemic amyloidosis: moving into the spotlight.
Review in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer.Translational vision science & technology · 2024Article
- Peritoneal Amyloid as a Presenting Manifestation of AL Amyloid.Journal of community hospital internal medicine perspectives · 2023Article
- AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects:JACC. CardioOncology · 2022Review
- A 65-Year-Old Woman with an Enlarged Tongue Due to Amyloidosis.The American journal of case reports · 2022Article
- Exercise suppresses mouse systemic AApoAII amyloidosis through enhancement of the p38 MAPK signaling pathway.Disease models & mechanisms · 2022Article
- Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.Frontiers in cardiovascular medicine · 2022Review
- [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Redirecting proteoxicity.Leukemia · 2020Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic amyloidosis is a rare but increasingly recognised disease that is heterogeneous in presentation. Early diagnosis, whilst imperative, remains challenging but can improve prognosis and limit organ dysfunction. An increased repertoire of diagnostic imaging and histological techniques are becoming mainstream and promise to aid early diagnosis. Better risk stratification, via biomarkers and cytogenetics, has improved multidisciplinary treatment decisions. The use of novel agents has improved treatment efficacy, which translates into survival benefit. Newer strategies targeting pre-deposited amyloidogenic protein are under investigation. The current paper reviews available data relating to the most recent advances in the field of systemic amyloidosis.
Indexed as
Identifiers
32269317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.